References:
[1]. Chen, W., et al., Cancer statistics in China, 2015. CA Cancer J
Clin, 2016. 66(2): p. 115-32.
[2]. Siegel, R.L., K.D. Miller and A. Jemal, Cancer statistics,
2018. CA Cancer J Clin, 2018. 68(1): p. 7-30.
[3]. Eskiizmir, G., et al., The evaluation of pretreatment
neutrophil-lymphocyte ratio and derived neutrophil-lymphocyte ratio in
patients with laryngeal neoplasms. Braz J Otorhinolaryngol, 2019. 85(5):
p. 578-587.
[4]. Siegel, R., et al., Cancer statistics, 2014. CA Cancer J Clin,
2014. 64(1): p. 9-29.
[5]. Balch, C.M., et al., Prognostic factors analysis of 17,600
melanoma patients: validation of the American Joint Committee on Cancer
melanoma staging system. J Clin Oncol, 2001. 19(16): p. 3622-34.
[6]. Grivennikov, S.I., F.R. Greten and M. Karin, Immunity,
inflammation, and cancer. Cell, 2010. 140(6): p. 883-99.
[7]. Aggarwal, B.B., R.V. Vijayalekshmi and B. Sung, Targeting
inflammatory pathways for prevention and therapy of cancer: short-term
friend, long-term foe. Clin Cancer Res, 2009. 15(2): p. 425-30.
[8]. Singel, K.L. and B.H. Segal, Neutrophils in the tumor
microenvironment: trying to heal the wound that cannot heal. Immunol
Rev, 2016. 273(1): p. 329-43.
[9]. Labelle, M., S. Begum and R.O. Hynes, Direct signaling between
platelets and cancer cells induces an epithelial-mesenchymal-like
transition and promotes metastasis. Cancer Cell, 2011. 20(5): p. 576-90.
[10]. Diem, S., et al., Neutrophil-to-Lymphocyte ratio (NLR) and
Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients
with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung
Cancer, 2017. 111: p. 176-181.
[11]. Xia, W.K., et al., Prognostic performance of pre-treatment NLR
and PLR in patients suffering from osteosarcoma. World J Surg Oncol,
2016. 14: p. 127.
[12]. Rachidi, S., et al., Neutrophil-to-lymphocyte ratio and
overall survival in all sites of head and neck squamous cell carcinoma.
Head Neck, 2016. 38 Suppl 1: p. E1068-74.
[13]. Kim, J. and J.S. Bae, Tumor-Associated Macrophages and
Neutrophils in Tumor Microenvironment. Mediators Inflamm, 2016. 2016: p.
6058147.
[14]. Parmar, M.K., V. Torri and L. Stewart, Extracting summary
statistics to perform meta-analyses of the published literature for
survival endpoints. Stat Med, 1998. 17(24): p. 2815-34.
[15].
Li,
Z., et al., Prognostic value of the neutrophil-to-lymphocyte ratio,
platelet-to-lymphocyte ratio and systemic immune-inflammation index in
patients with laryngeal squamous cell carcinoma. Clin Otolaryngol, 2021.
46(2): p. 395-405.
[16]. Xun, Y., et al., Prognostic Analysis of Preoperative
Inflammatory Biomarkers in Patients With Laryngeal Squamous Cell
Carcinoma. Ear Nose Throat J, 2020. 99(6): p. 371-378.
[17].
Shen,
L.F., Q.Y. Wang and Q. Yu, The Systemic Immune-Inflammation Index and
Albumin as Prognostic Predictors in Laryngeal Carcinoma. Nutr Cancer,
2020: p. 1-8.
[18]. Zhou, T., et al., Pretreatment albumin globulin ratio has a
superior prognostic value in laryngeal squamous cell carcinoma patients:
a comparison study. J Cancer, 2019. 10(3): p. 594-601.
[19].
Zhong,
B., et al., Correction: May the change of platelet to lymphocyte ratio
be a prognostic factor for T3-T4 laryngeal squamous cell carcinoma: A
retrospective study. PLoS One, 2019. 14(12): p. e0226383.
[20]. Chen, L., et al., Survival and prognostic analysis of
preoperative inflammatory markers in patients undergoing surgical
resection for laryngeal squamous cell carcinoma. BMC Cancer, 2018.
18(1): p. 816.
[21].
Wang,
J., et al., The prognostic value of systemic and local inflammation in
patients with laryngeal squamous cell carcinoma. Onco Targets Ther,
2016. 9: p. 7177-7185.
[22]. Diakos, C.I., et al., Cancer-related inflammation and
treatment effectiveness. Lancet Oncol, 2014. 15(11): p. e493-503.
[23].
Warnakulasuriya,
S., Global epidemiology of oral and oropharyngeal cancer. Oral Oncol,
2009. 45(4-5): p. 309-16.
[24]. Hurt, B., et al., Cancer-promoting mechanisms of
tumor-associated neutrophils. Am J Surg, 2017. 214(5): p. 938-944.
[25].
Monreal,
M., et al., Platelet count and survival in patients with colorectal
cancer–a preliminary study. Thromb Haemost, 1998. 79(5): p. 916-8.
[26]. Sharma, D., et al., Platelets in tumor progression: a host
factor that offers multiple potential targets in the treatment of
cancer. J Cell Physiol, 2014. 229(8): p. 1005-15.
[27].
Mohammed,
Z.M., et al., The relationship between components of tumour inflammatory
cell infiltrate and clinicopathological factors and survival in patients
with primary operable invasive ductal breast cancer. Br J Cancer, 2012.
107(5): p. 864-73.
[28]. Rabinowich, H., et al., Functional analysis of mononuclear
cells infiltrating into tumors: lysis of autologous human tumor cells by
cultured infiltrating lymphocytes. Cancer Res, 1987. 47(1): p. 173-7.
[29].
Ciurea,
S.O. and R. Hoffman, Cytokines for the treatment of thrombocytopenia.
Semin Hematol, 2007. 44(3): p. 166-82.
[30]. Gersuk, G.M., et al., Inhibition of human natural killer cell
activity by platelet-derived growth factor (PDGF). III. Membrane binding
studies and differential biological effect of recombinant PDGF isoforms.
Scand J Immunol, 1991. 33(5): p. 521-32.
[31].
Varon,
D. and E. Shai, Role of platelet-derived microparticles in angiogenesis
and tumor progression. Discov Med, 2009. 8(43): p. 237-41.